Quest Diagnostics Incorporated (NYSE:DGX) Receives $146.17 Consensus PT from Analysts

Quest Diagnostics Incorporated (NYSE:DGXGet Free Report) has received an average recommendation of “Hold” from the twelve research firms that are presently covering the stock, Marketbeat.com reports. Nine research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $146.17.

Several brokerages recently commented on DGX. Jefferies Financial Group raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating and increased their price objective for the company from $140.00 to $155.00 in a research note on Wednesday, February 7th. UBS Group raised their price target on shares of Quest Diagnostics from $139.00 to $146.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Mizuho boosted their price objective on shares of Quest Diagnostics from $150.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. StockNews.com lowered Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Finally, TheStreet lowered Quest Diagnostics from a “b-” rating to a “c” rating in a research report on Monday, February 5th.

Get Our Latest Stock Analysis on DGX

Insiders Place Their Bets

In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 5,611 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $125.88, for a total transaction of $706,312.68. Following the transaction, the senior vice president now owns 38,478 shares of the company’s stock, valued at approximately $4,843,610.64. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, SVP Karthik Kuppusamy sold 1,760 shares of the business’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $140.00, for a total value of $246,400.00. Following the sale, the senior vice president now directly owns 13,435 shares in the company, valued at approximately $1,880,900. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael E. Prevoznik sold 5,611 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $125.88, for a total transaction of $706,312.68. Following the transaction, the senior vice president now owns 38,478 shares of the company’s stock, valued at approximately $4,843,610.64. The disclosure for this sale can be found here. Insiders have sold 15,428 shares of company stock valued at $1,972,662 in the last three months. 0.79% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Norges Bank bought a new position in shares of Quest Diagnostics in the fourth quarter worth $140,472,000. Nuance Investments LLC bought a new position in Quest Diagnostics in the 4th quarter worth about $83,070,000. JPMorgan Chase & Co. grew its holdings in Quest Diagnostics by 36.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,001,347 shares of the medical research company’s stock valued at $243,884,000 after buying an additional 538,377 shares in the last quarter. American Century Companies Inc. grew its holdings in Quest Diagnostics by 12.3% during the 3rd quarter. American Century Companies Inc. now owns 3,554,517 shares of the medical research company’s stock valued at $433,153,000 after buying an additional 388,162 shares in the last quarter. Finally, M&G Plc bought a new stake in shares of Quest Diagnostics during the first quarter valued at about $46,432,000. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Quest Diagnostics Trading Down 1.0 %

Shares of NYSE:DGX opened at $141.86 on Friday. The stock has a market cap of $15.76 billion, a PE ratio of 19.09, a P/E/G ratio of 3.13 and a beta of 0.88. The company has a quick ratio of 0.89, a current ratio of 0.97 and a debt-to-equity ratio of 0.59. Quest Diagnostics has a 12-month low of $119.59 and a 12-month high of $145.62. The business has a 50 day moving average of $133.82 and a 200-day moving average of $132.93.

Quest Diagnostics (NYSE:DGXGet Free Report) last released its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.18. Quest Diagnostics had a net margin of 9.11% and a return on equity of 15.52%. The business had revenue of $2.37 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period last year, the firm earned $2.04 earnings per share. Quest Diagnostics’s revenue for the quarter was up 1.7% compared to the same quarter last year. As a group, equities research analysts forecast that Quest Diagnostics will post 8.78 earnings per share for the current year.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, July 22nd. Investors of record on Monday, July 8th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 2.11%. The ex-dividend date is Monday, July 8th. Quest Diagnostics’s payout ratio is currently 38.22%.

About Quest Diagnostics

(Get Free Report

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Further Reading

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.